# Roy Fleischmann

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/roy-fleischmann/

## Facts

| Field | Value |
| --- | --- |
| Citations | 32,688 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 80 |
| i10-index | 224 |
| Last Known Institution | Metroplex Clinical Research Center |
| OpenAlex ID | https://openalex.org/A5046261111 |
| ORCID iD | https://orcid.org/0000-0002-6630-1477 |
| Works | 490 |

## Researcher papers

- [Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis](https://scholariq.org/papers/placebo-controlled-trial-of-tofacitinib-monotherapy-in-rheumatoid-arthritis/)
- [Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-or-adalimumab-versus-placebo-in-rheumatoid-arthritis/)
- [Tofacitinib versus Methotrexate in Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-versus-methotrexate-in-rheumatoid-arthritis/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)
- [Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-in-combination-with-nonbiologic-disease-modifying-antirheumatic/)
- [Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu](https://scholariq.org/papers/tocilizumab-inhibits-structural-joint-damage-in-rheumatoid-arthritis-patients/)
- [Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs](https://scholariq.org/papers/phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550-or/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [Metroplex Clinical Research Center](https://scholariq.org/institutions/metroplex-clinical-research-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.